SCHEDULE: AllianceBernstein Discloses PROCEPT BioRobotics Stake

AllianceBernstein L.P. has filed a Schedule 13G, reporting beneficial ownership of 147,327 shares of PROCEPT BioRobotics Corp. common stock, representing 0.3% of the class.

Summary

• AllianceBernstein L.P. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of PROCEPT BioRobotics Corp. common stock.
• The filing reports that AllianceBernstein L.P. beneficially owns 147,327 shares of common stock.
• This ownership represents 0.3% of the total class of securities.
• The shares were acquired solely for investment purposes on behalf of client discretionary investment advisory accounts.
• AllianceBernstein L.P. has sole voting power over 146,027 shares and sole dispositive power over 147,327 shares.
• The filing is dated March 31, 2026, and the amendment was filed on May 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It indicates a standard investment by an institutional manager but provides no new operational or strategic information about PROCEPT BioRobotics Corp.

Positives

• AllianceBernstein L.P., a significant investment management firm, holds a stake in PROCEPT BioRobotics Corp., suggesting confidence in the company's long-term prospects.
• The acquisition of shares is stated to be for investment purposes on behalf of client discretionary accounts, indicating a professional and strategic approach to investment.

Negatives

• The reported ownership stake of 0.3% is relatively small, suggesting AllianceBernstein L.P. is not a major activist investor or a controlling shareholder.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.

Future Outlook

The filing does not contain any forward-looking statements or guidance from AllianceBernstein L.P. regarding PROCEPT BioRobotics Corp.

Management Comments

• AllianceBernstein L.P. acquired shares solely for investment purposes on behalf of client discretionary investment advisory accounts.
• AllianceBernstein L.P. is a majority-owned subsidiary of Equitable Holdings, Inc. (EQH), but operates under independent management and makes independent decisions from EQH.
• Marcus Edwards, AVP/ Senior Compliance Associate, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating stakes in publicly traded companies. AllianceBernstein L.P.'s investment in PROCEPT BioRobotics Corp. aligns with broader trends of institutional capital flowing into the medical technology sector, particularly in areas like robotics.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which can be viewed positively as a sign of confidence, though the small percentage limits immediate impact.
• Management: The filing is a routine disclosure and does not directly impact management's operational decisions, but reinforces the need for transparency.
• Creditors: No direct impact is indicated.

Next Steps

• AllianceBernstein L.P. will continue to hold the shares for investment purposes on behalf of its clients.
• Further filings may be required if AllianceBernstein L.P.'s ownership stake changes significantly.

Key Dates

Keywords

PROCEPT BioRobotics Corp, AllianceBernstein L.P., Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Securities Exchange Act